BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats.
To clarify clinical roles of sigma receptor binding affinity of neuroleptics, neck dystonia induced by microinjection of sigma receptor ligands and neuroleptics into rat red nucleus was investigated. DTG and (+)-3-PPP, putative sigma receptor agonists, induced neck dystonia in dose-dependent and reversible manner. Haloperidol and perphenazine induced dystonia in the same way as sigma receptor agonists, whereas zotepine and (-)-sulpiride did not. The rank order of potency in induction of dystonia and sigma receptor affinity of these compounds showed positive correlation. Although BMY-14802 has a high affinity for sigma receptors, it never produced dystonia by itself. On the other hand, combined injection of BMY-14802 with DTG attenuated DTG-induced dystonia. Therefore, it is suggested that typical neuroleptics such as haloperidol act agonistic and atypical neuroleptics such as BMY-14802 act antagonistic at rubral sigma receptors in the induction of neck dystonia.
Okumura
K
K
Department of Neuropsychiatry, Okayama University Medical School, Japan.
Ujike
H
H
Akiyama
K
K
Kuroda
S
S
D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D003988:Dibenzothiepins / Q000633:toxicity; D018492:Dopamine Antagonists / Q000633:toxicity*; D065127:Dopamine D2 Receptor Antagonists; D004421:Dystonia / Q000139:chemically induced / Q000188:drug therapy*; D006146:Guanidines / Q000633:toxicity*; D006220:Haloperidol / Q000633:toxicity; D008297:Male; D008845:Microinjections; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D010546:Perphenazine / Q000633:toxicity; D010880:Piperidines / Q000633:toxicity*; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000502:physiology; D017480:Receptors, sigma / Q000819:agonists / Q000037:antagonists & inhibitors* / Q000502:physiology; D012012:Red Nucleus / Q000187:drug effects* / Q000502:physiology; D013469:Sulpiride / Q000633:toxicity; D014103:Torticollis / Q000139:chemically induced / Q000188:drug therapy*
D014150:Antipsychotic Agents; D003988:Dibenzothiepins; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D006146:Guanidines; D009419:Nerve Tissue Proteins; D010880:Piperidines; D011743:Pyrimidines; D017448:Receptors, Dopamine D2; D017480:Receptors, sigma; C050408:alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol; D013469:Sulpiride; C026539:preclamol; D010546:Perphenazine; D006220:Haloperidol; C050232:1,3-ditolylguanidine; C022172:zotepine